At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in Parkinson’s ...

Her latest study examines how reprogramming the tumor microenvironment improves long-term immune memory by targeting the IL6ra-Bcl6 axis in CD4 T cells, offering new hope for more effective GBM ...

One is using ARV-393, a PROTAC for blood cancers that degrades BCL6, a previously undruggable target. The second involves ARV-102, which degrades a protein relevant to neuroscience. “Our ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein ...

- Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 ...

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...